Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Predictive Oncology appoints three directors to board » 08:45
07/14/20
07/14
08:45
07/14/20
08:45
POAI

Predictive Oncology

$1.44 /

-0.02 (-1.37%)

Predictive Oncology…

Predictive Oncology announced the appointment of three new members to the company's board of directors, effective immediately. Joining the board are: Dr. Nancy Chung-Welch, Ph.D.; Mr. Charles L. Nuzum, CPA; Mr. Greg St. Clair. Predictive Oncology's board is comprised of seven members. Each of the new board members will serve as independent directors as defined by Nasdaq Corporate Governance rules. Dr. Chung-Welch currently serves as an independent consultant advising life science companies and institutional investors with an emphasis on the research product/tools market. Mr. Nuzum currently provides project-based financial consulting services to companies such as McKesson, BioMarin, AutoDesk and Squire Patton Boggs and mentors start-up companies. Mr. St. Clair is Founder and a Managing Member of SunStone Consulting.

ShowHide Related Items >><<
POAI Predictive Oncology
$1.44 /

-0.02 (-1.37%)

POAI Predictive Oncology
$1.44 /

-0.02 (-1.37%)

Over a month ago
Hot Stocks
Predictive Oncology receives cash proceeds of $2.2M form warrant exercise » 16:36
06/29/20
06/29
16:36
06/29/20
16:36
POAI

Predictive Oncology

$1.73 /

-0.055 (-3.09%)

Predictive Oncology…

Predictive Oncology announced the closing of its previously announced transaction resulting in gross cash proceeds to the Company of approximately $2.2 million, prior to deducting placement agent fees and offering expenses, through the exercise of certain existing warrants by several holders to purchase an aggregate of up to 1,396,826 shares of common stock at an exercise price of $1.575 per share. The shares of common stock issued upon exercise of the existing warrants are registered for resale pursuant to a registration statement on Form S-1. In consideration for the immediate exercise of the existing warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock at an exercise price of $1.80 per share with an exercise period of five and one-half years from the date of issuance. The Company expects to use the net proceeds from this offering for working capital and general corporate purposes.

ShowHide Related Items >><<
POAI Predictive Oncology
$1.73 /

-0.055 (-3.09%)

POAI Predictive Oncology
$1.73 /

-0.055 (-3.09%)

Syndicate
Predictive Oncology files to sell 3.29M shares of common stock for holders  16:33
06/24/20
06/24
16:33
06/24/20
16:33
POAI

Predictive Oncology

$1.81 /

-0.17 (-8.59%)

 
ShowHide Related Items >><<
POAI Predictive Oncology
$1.81 /

-0.17 (-8.59%)

POAI Predictive Oncology
$1.81 /

-0.17 (-8.59%)

Hot Stocks
Predictive Oncology's TumorGenesis division secures commercial sale » 08:34
06/18/20
06/18
08:34
06/18/20
08:34
POAI

Predictive Oncology

$1.74 /

+0.03 (+1.75%)

Predictive Oncology…

Predictive Oncology announces that Predictive's TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells collected from patient derived samples through its distributor US Biological Corporation. The media used to grow the novel and unique ovarian cancer cell lines, licensed by TumorGenesis and its partner, GLG Pharma are able to retain 95%+ of the DNA and RNA as well as crucial proteomic signatures. The media was sold to a top rated medical university in the New England area for research in isolating and growing ovarian cancer cells from the fluid often found in the abdomen of women with advanced ovarian cancer, called the 'ascites' fluid. Ovarian cancer cell culturing from ascites fluids are notoriously difficult using standard media mixes often prone to failure and cell lines that are not representative of the patient's ovarian cancer.

ShowHide Related Items >><<
POAI Predictive Oncology
$1.74 /

+0.03 (+1.75%)

POAI Predictive Oncology
$1.74 /

+0.03 (+1.75%)

Syndicate
Predictive Oncology files to sell 1.74M shares of common stock for holders  15:05
06/16/20
06/16
15:05
06/16/20
15:05
POAI

Predictive Oncology

$1.74 /

+0.005 (+0.29%)

 
ShowHide Related Items >><<
POAI Predictive Oncology
$1.74 /

+0.005 (+0.29%)

POAI Predictive Oncology
$1.74 /

+0.005 (+0.29%)

Hot Stocks
Predictive Oncology completes acquisition of Soluble Therapeutics, BioDtech » 08:33
06/02/20
06/02
08:33
06/02/20
08:33
POAI

Predictive Oncology

$1.60 /

+0.07 (+4.58%)

Predictive Oncology…

Predictive Oncology announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of InventaBioTech, Inc. The Company acquired the assets of Soluble and BioDtech, including, certain intellectual property relating to contract research organization services and technology, certain equipment useful in such services and technology and all other assets of Soluble Therapeutics and BioDtech for 125,000 shares of common stock, in addition to waiving all remaining amounts due and payable to the Company under a secured promissory note of InventaBioTech in the principal amount of $1,070,000 relating to advances made by the Company in 2017.

ShowHide Related Items >><<
POAI Predictive Oncology
$1.60 /

+0.07 (+4.58%)

POAI Predictive Oncology
$1.60 /

+0.07 (+4.58%)

Hot Stocks
Predictive Oncology licensing NSP10 technology for COVID-19 vaccine » 08:37
05/14/20
05/14
08:37
05/14/20
08:37
POAI

Predictive Oncology

$1.35 /

-0.08 (-5.59%)

Predictive Oncology has,…

Predictive Oncology has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID19 vaccine. The ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10 which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin. NSP10 Nanoparticle has special surface properties that allow for the rapid design and display of viral receptor stems for virtually any virus, making it extremely versatile. Previous vaccine studies of NSP10-based Nanoparticles in rabbits produced exceptionally high titers against a herpes viral protein called glycoprotein D, normally non-highly antigenic. Titers in this case ranged from 1:1,000 with a simple injection of 500 micrograms of plasmid DNA, to as much as 1:25,000 after a second booster - all without the use of adjuvants or transfection agents. To our knowledge, this is unprecedented and revolutionary for a DNA vaccine. The exact reasons why the NSP10-based Nanoparticles exhibit these properties is still a subject of study, but scientists know that nanoparticles are processed differently by the immune system and smaller nanoparticles can often produce higher titers - NSP is one of the smallest currently evaluated. The level of titer is important for many reasons, for example, earlier animal experiments with vaccines focused on severe acute respiratory syndrome and Middle East respiratory syndrome found that low antibody levels could potentially lead to dysfunctional immune responses, increasing infection and damaging the lungs. In addition to enhanced protective immunity, stronger titers mean that it takes less vaccine per dose which has added advantages in safety and production scale. In the special case of NSP10-based vaccines, as it translates to humans, this could mean that a single gram of plasmid DNA can potentially immunize as many as 2,000 people, perhaps more.

ShowHide Related Items >><<
POAI Predictive Oncology
$1.35 /

-0.08 (-5.59%)

POAI Predictive Oncology
$1.35 /

-0.08 (-5.59%)

Hot Stocks
Predictive Oncology, Daniel Carter collaborating to develop COVID-19 vaccine » 09:08
05/06/20
05/06
09:08
05/06/20
09:08
POAI

Predictive Oncology

$1.45 /

-0.02 (-1.36%)

Predictive Oncology has,…

Predictive Oncology has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID-19 vaccine. The groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin, an iron storage protein found in all living things. The ferritin platform is currently exploited by NIH in its exploration of the universal flu vaccine which completed phase I clinical trials earlier this year and is currently recruiting for a second Phase 1 trial on a modified version of the ferritin self-assembly universal vaccine POAI has entered into an agreement with Dr. Carter under which POAI is licensing this technology, subject to certain conditions including additional documentation. NSP-10 is a newly patented self-assembling nanoparticle technology sometimes referred to as virus-like particles or VL. Called a nanoparticle because of its small size, typically 10-12 nanometers in diameter and self-assembling because a single small subunit has the built-in "self-assembly" instructions to form engineered complex Virus Like Particle assemblies. They can be thought of as "smart-Legos", so that when a large number are thrown together, they automatically self-assemble into the same large complex structures - in this case the vaccine. In the case of a DNA vaccine, the DNA instructs the body's cells to make the Legos in mass which assemble into numerous vaccine particles.

Over a quarter ago
Syndicate
Predictive Oncology files to sell 5.89M shares of common stock for holders  16:24
04/06/20
04/06
16:24
04/06/20
16:24
POAI

Predictive Oncology

$1.40 /

+0.075 (+5.66%)

 
Hot Stocks
Predictive Oncology to focus resources on Helomics, TumorGenesis divisions » 08:52
04/01/20
04/01
08:52
04/01/20
08:52
POAI

Predictive Oncology

$1.54 /

-0.265 (-14.72%)

The company said,…

The company said, "Going forward, management intends to focus its resources on the Helomics and TumorGenesis divisions and the Company's primary mission of applying artificial intelligence to precision medicine, drug discovery and the mediums used to replace rats and mice in preliminary cancer studies. Predictive Oncology had previously reported in December 2019 that it had received several indications of interest for the possible acquisition of its Skyline Medical division, no further action has resulted from these indications, and today management reaffirms that it is focusing the majority of its resources on maximizing opportunities within the Company's precision medicine business."

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.